← Back to Treatments
🏅 FDA Orphan Designation

Fareston

Toremifene

Manufacturer: Orion Corporation

Indicated for:
Metaplastic carcinoma of the breastOrphanRare malignant breast tumor
⚠️

Black Box Warning (Boxed Warning)

A Boxed Warning is the FDA's strongest safety warning — it indicates serious or life-threatening risks identified during clinical trials or post-market surveillance. It does not mean the medication is unsafe for all patients; your prescriber weighs these risks against the benefits for your specific situation. Source: FDA-approved prescribing information.

View full prescribing information on DailyMed (NLM) ↗

FDA-Approved Indications (2)

Treatment of metastatic breast cancer in postmenopausal women with estrogen positive or receptor unknown tumors.

indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors

Population: postmenopausal women

Indications & Usage

1 INDICATIONS AND USAGE FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. ( 1 )

💙 Support Programs

View all →
Fareston
Orion

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.